- €46.17bn
- €78.52bn
- €45.58bn
Brief: U.S. FDA Grants Priority Review To Supplemental New Drug Application For Hyrnuo® (Sevabertinib)
Brief: Bayer - FDA Priority Review For Sevabertinib
Lawyers eye near-record payout in $7.25 billion Bayer settlement
Class action lawyers seek $675 million in Bayer Roundup settlement (updated)
Class action lawyers seek $675 million in Bayer Roundup settlement
Live Markets: Soft first few hours for European stocks
Bayer rises after Q1 profit beat on agriculture strength
Bayer Q1 operating profit jumps 9% on boost from soy business (updated)
Germany's Bayer Q1 sales rise 4.1% on Crop Science unit strength
Bayer Q1 operating profit up 9% as crop protection unit gains
Brief: Bayer Q1 Adjusted EBITDA EUR 4,453 Million
Brief: Bayer Says China's Center Of Drug Evaluation Grants Priority Review Designation For Asundexian
Brief: Bayer Says Iodine-124 Evuzamitide Meets Phase III Endpoints in Cardiac Amyloidosis
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Bayer's experimental blood thinner cuts risk and severity of repeat strokes (updated)
Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
Brief: Bayer To Acquire Perfuse Therapeutics For Deal Valued Up To $2.45 Billion
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal (updated)